Screener / SEC EDGAR /CIK 0000818686 /10-K filed Feb 3, 2026, compared with Feb 5, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

Teva Pharmaceutical Industries Ltd TEVA

Compare with peers Embed
What it said it expected, against what it reported

1 target with a reported result

Releases of the last 3 years
Above the range 1 above the last range given
Within the range 0 of 1 range targets
Below the range 0 below the last range given

The numbers TEVA said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Operating income (company-defined)
Fiscal 2027
Given $700.00M release Nov 3, 2026
– No standard number
The company's words
Teva continued to transform and modernize its business through the Teva Transformation programs, which combined with innovative product growth potential, is expected to support the Company’s objective of achieving a 30% non-GAAP operating income margin and approximately $700 million of net savings, by 2027 including ~two-thirds expected to be realized in 2026. release Nov 3, 2026
Revenue
Fiscal 2026
Given $16.50B to $16.85B release Jul 29, 2026
– Not reported yet
The company's words
2026 FinancialOutlook … Revenues 16.4 - 16.8 $16.5 - $16.85B release Jul 29, 2026
EBITDA (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $4.50B to $5.00B release May 8, 2024
– No standard number
The company's words
Full year 2024 business outlook reaffirmed: … Adjusted EBITDA of $4.5 - $5.0 billion release May 8, 2024
Free cash flow (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $1.70B to $2.00B release May 8, 2024
– No standard number
The company's words
Full year 2024 business outlook reaffirmed: … Free cash flow of $1.7 - $2.0 billion release May 8, 2024
Diluted EPS (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $2.20 to $2.50 release May 8, 2024
– No standard number
The company's words
Full year 2024 business outlook reaffirmed: … Non-GAAP diluted EPS of $2.20 - $2.50 release May 8, 2024
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $15.70B to $16.30B release May 8, 2024
$16.54B
10-K filed 2025-02-05
Above the range
The company's words
Full year 2024 business outlook reaffirmed: … Revenues of $15.7 - $16.3 billion release May 8, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (13 releases since 2024-01-31), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TEVA/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.